Hikma Pharmaceuticals PLC (HIK.L)
|Market Cap (Mil.):||£1,907.01|
|Shares Outstanding (Mil.):||197.48|
May 16 - Hikma Pharmaceuticals Plc raised its full-year revenue forecast, saying its generic antibiotic doxycycline was generating revenue ahead of its expectations.
LONDON, May 16 - Hikma Pharmaceuticals PLC : * Hikma pharmaceutical - interim management statement * Branded and injectables businesses are on track to meet our current FY
LONDON, April 17 - Hikma Pharmaceuticals said on Wednesday it would keep its fast-growing injectables business after weighing up a number of unsolicited approaches for the unit.
LONDON, April 17 - Hikma Pharmaceuticals PLC : * CORRECTED-HIKMA PHARMACEUTICALS PLC - DETERMINED THAT GLOBAL
March 13 - Hikma Pharmaceuticals Plc reported a 19 percent rise in full-year profit, helped by strong growth in its lucrative injectables business, which has drawn interest from several bidders.
LONDON, March 13 - Hikma Pharmaceuticals PLC : * Auto alert - Hikma Pharmaceuticals Plc final dividend 0.10 usd per
* Says got expressions of interest for injectables business
March 1 - Hikma Pharmaceuticals Plc said it reviewing options for its injectables business.
LONDON, Jan 9 - Hikma Pharmaceuticals PLC : * Hikma pharmaceutical - acquisition * To acquire the egyptian company for pharmaceuticals & chemical industries * will pay cash consideration of EGP 142.4 million upon
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Hikma Pharmaceuticals PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.